Nintedanib Zidrium Teva

Nintedanib, the active ingredient in Nintedanib Zidrium Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination therapy for non‑small cell lung cancer. GNH USA supplies Nintedanib Zidrium Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring consistent quality, regulatory compliance, and robust supply chain management.

Nintedanib targets fibrotic lung diseases and certain cancers by inhibiting key growth factor receptors. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer (in combination therapy): enhances treatment efficacy when combined with chemotherapy.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may be transient. - Vomiting: occasional episodes. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Liver enzyme elevation: mild increase in ALT/AST. Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: such as myocardial infarction or stroke. - Severe infections: opportunistic infections in immunocompromised patients.

When prescribing Nintedanib, clinicians should consider several precautionary measures to ensure patient safety. - Liver function monitoring: assess ALT, AST, bilirubin before and during therapy. - Gastrointestinal management: advise patients on hydration and antidiarrheal measures. - Cardiovascular assessment: evaluate history of ischemic heart disease before initiation. - Bleeding risk evaluation: avoid in patients with active ulcers or on anticoagulants without supervision. - Pregnancy and lactation: contraindicated or used only if benefits outweigh risks; discuss with obstetrician. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Nintedanib can interact with other medicines, affecting its efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - High‑dose aspirin or NSAIDs: additive bleeding potential. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels. - P-glycoprotein inhibitors (e.g., verapamil): could affect drug transport. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.